GV22-02
A Clinical Risk Assessment Score for Development of Moderate-Severe Chronic Graft-versus-Host Disease After Hematopoietic Cell Transplantation and Post-Transplant Cyclophosphamide
Study #: GV22-02
Study Status: Submitted
A Clinical Risk Assessment Score for Development of Moderate-Severe Chronic Graft-versus-Host Disease After Hematopoietic Cell Transplantation and Post-Transplant Cyclophosphamide
Study #: GV22-02
Study Status: Submitted